The Role of Metastasectomy for Melanoma Reexamined in the Modern Era
In the modern era of therapeutic agents, metastasectomy was still associated with improved survival outcomes for patients with stage IV melanoma.
Skin Cancer
Tumors With High Levels of Microsatellite Instability Responded Well to Treatment With PD-1 Inhibitors
New research has linked microsatellite instability and the number of insertion/deletion mutations present in a tumor to clinical response to checkpoint inhibition.
Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases
Secondary end points were not significantly different between the 2 groups, including overall survival.
How to Treat Melanoma After Checkpoint Inhibitors Fail
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant Ipilimumab Determined to Increase Overall Survival in High-Risk Melanoma
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
Depth of Response to TKIs, Immunotherapies Correlates to Longer PFS and OS
Researchers from the FDA analyzed 10 RCTs conducted in patients with unresectable or metastatic melanoma who were treated with 1 of 3 drug types.
Ipilimumab, BRAF/MEK Inhibitors Are Active in Patients With Resected Melanoma Who Recurred on Adjuvant Anti–PD-1
For patients who recur on anti–PD-1, they should be considered resistant to anti–PD-1 and must change to a different type of medication, said Dr Owen.
Inactivating Mutations in Genes Encoding for Components of the mSWI/SNF Complex May Be Associated With Improved OS in Immunotherapy-Treated Patients
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.
Elevated Levels of Serum CRP and IL-6 Are Biomarkers of Poor Prognosis in Patients Receiving Immune Checkpoint Inhibitors
New data revealed an association between low baseline IL-6 level and improved survival in patients across all 3 arms of CheckMate 067.
